John Fling

Personal profile

Area of Expertise

Dr. Fling is board certified in Allergy/Immunology and Pediatrics with over thirty years of experience caring for adults, children, and infants. His main focus is the care and management of individuals suffering from allergies and asthma. He uses evidence-based practice for the diagnoses and treatment strategies, along with patient input to create the optimal treatment plan. In addition to clinical practice, Dr. Fling has been involved as principal investigator in multiple research studies and has a special interest in the development of new vaccines. He is a member of American Academy of Allergy, Asthma, and Immunology, Tarrant County Medical Society, and a fellow of the American Academy of Pediatrics.

Education/Academic qualification

BS in Biology, Southwest Texas State University

MD, University of Texas Health Science Center at San Antonio

Fingerprint Dive into the research topics where John Fling is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

7 Active
14 Finished

Phase III, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of Seqirus¿ Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and a US-licensed QIV in Healthy Subjects aged 6 Months through 47 Months

Fling, J.

Syneos Health

1/08/19 → 31/12/20

Project: Research

¿A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study-Assess Safety/Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine-Administered Concomitantly with Routine Vaccines to Healthy Infants.

Fling, J.

GlaxoSmithKline

6/01/19 → 5/06/23

Project: Research

Immunogenicity, reactogenicity and safety study of Pediarix, Hiberix and Prevenar 13 co-administered with two different formulations of GSK Biologicals' HRV vaccine (444563) in healthy infants 6-12 weeks of age.

Fling, J.

GlaxoSmithKline

7/07/17 → 6/07/21

Project: Research

A PHASE 3, PLACEBO CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER

Fling, J.

Pfizer, Inc.

13/04/17 → 13/04/21

Project: Research

A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

Fling, J.

MedImmune, LLC

8/11/16 → 7/11/21

Project: Research

Research Output

242 Citations
6 h-Index
9 Article

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

Klein, N. P., Abu-Elyazeed, R., Povey, M., Macias Parra, M., Diez-Domingo, J., Ahonen, A., Korhonen, T., Tinoco, J. C., Weiner, L., Marshall, G. S., Silas, P. E., Sarpong, K. O., Ramsey, K. P., Fling, J. A., Speicher, D., Campos, M., Munjal, I., Peltier, C., Vesikari, T., Baccarini, C. & 4 others, Caplanusi, A., Gillard, P., Carryn, S. & Henry, O., 30 Apr 2020, In : Journal of the Pediatric Infectious Diseases Society. 9, 2, p. 194-201 8 p.